In 2023, the standardised rate of stomach malignant neoplasms mortality among women in the US stood at 2.5 per hundred thousand. The forecast indicates a steady decrease in mortality, with a consistent value of 2.4 from 2024 to 2027, and a slight reduction to 2.3 in 2028. Year-on-year variation shows no change between 2024 and 2025, with a minor decrease of around 4.17% from 2027 to 2028. The compound annual growth rate (CAGR) over the forecasted period reflects a steady decline, suggesting ongoing efforts in early detection and improved treatment methods.

Future trends to watch for include:

Advancements in precision medicine that may further reduce mortality rates.
Changes in dietary habits and obesity rates which could impact disease prevalence.
Implementation of widespread screening programs aimed at early detection.